Insider Trading Activity Reata Pharmaceuticals, Inc. (NASDAQ:RETA) – Director Bought 8,064 shares of Stock

ME Staff
-
0

Insider Trading Activity For Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

James Edward Bass , Director of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) reportedly Bought 8,064 shares of the company’s stock at an average price of 31 for a total transaction amount of $249,984.00 SEC Form

Insider Trading History For Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

  • On 6/1/2016 R Kent Mcgaughy Jr, Director, bought 251,553 with an average share price of $12.70 per share and the total transaction amounting to $3,194,723.10.View SEC Filing
  • On 6/1/2016 James Warren Huff, Insider, bought 114,000 with an average share price of $11.00 per share and the total transaction amounting to $1,254,000.00.View SEC Filing
  • On 6/1/2016 A/S Novo, Major Shareholder, bought 750,000 with an average share price of $11.00 per share and the total transaction amounting to $8,250,000.00.View SEC Filing
  • On 6/7/2016 R Kent Mcgaughy Jr, Director, bought 24,220 with an average share price of $17.57 per share and the total transaction amounting to $425,545.40.View SEC Filing
  • On 6/27/2016 Cpmg Inc, Director, bought 73,403 with an average share price of $19.26 per share and the total transaction amounting to $1,413,741.78.View SEC Filing
  • On 6/30/2016 James W Traweek Jr, Major Shareholder, bought 164,600 with an average share price of $19.78 per share and the total transaction amounting to $3,255,788.00.View SEC Filing
  • On 8/16/2016 Colin John Meyer, Insider, bought 7,000 with an average share price of $16.26 per share and the total transaction amounting to $113,820.00.View SEC Filing

    • Analyst Ratings For Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
    These are 6 Buy Ratings .
    The current consensus rating for Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is Buy (Score: 3.00) with a consensus target price of $61.00 , a potential (101.65% upside)

    Analyst Ratings History For Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

    • On 12/1/2016 Cowen and Company Reiterated Rating Buy
    • On 7/24/2017 Piper Jaffray Companies Boost Price Target of rating Buy with a price target of $53.00 to $60.00
    • On 7/25/2017 Citigroup Inc. Reiterated Rating Buy to Buy with a price target of $39.00 to $87.00
    • On 7/25/2017 Stifel Nicolaus Reiterated Rating Buy with a price target of $38.00 to $50.00
    • On 7/25/2017 Robert W. Baird Reiterated Rating Outperform with a price target of $43.00 to $47.00
    • On 7/26/2017 Ladenburg Thalmann Financial Services Reiterated Rating Buy with a price target of $55.00 to $61.00

    Recent Trading Activity for Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
    Shares of Reata Pharmaceuticals, Inc. closed the previous trading session at 30.25 up +0.97 3.31% with 553,763 shares trading hands.